Ann: Voluntary Suspension, page-154

"This device has the potential to be a game-changer for patients, the Company and the US $3.5B TAVR market,”

theres the problem, sounds great, huge number but what does it mean?
It's the carrot that got us all glossy eyed, and followed the pied piper.

Is that $3.5B total spend on TAVR devices or is it the whole associated healthcare costs associted with the market.

Surgeons, hospitals pharmaceuticals all taking their cut of the TAVR market as well.

What % of that is the devices?
Who really knows?

All I have is questions that came to late.